108 patents
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
28 Dec 23
Described herein are methods for treating atopic dermatitis that allows for the effective treatment of the disease with an interruption period if certain adverse events are observed.
Gurpreet AHLUWALIA, Maple M FUNG, Andrew Christopher Wesley SELFRIDGE
Filed: 8 Nov 21
Utility
Modulators of the Prostacyclin (PGI2) Receptor Useful for the Treatment of Disorders Related Thereto
21 Dec 23
Thuy-Anh TRAN, Weichao CHEN, Bryan A. KRAMER, Abu J.M. SADEQUE, Anna SHIFRINA, Young-Jun SHIN, Pureza VALLAR, Ning ZOU
Filed: 28 Apr 23
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
14 Dec 23
Amit D. MUNSHI
Filed: 8 Nov 21
Utility
Method of treating conditions related to the PGI2 receptor
28 Nov 23
Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
Alan Glicklich
Filed: 12 Jul 22
Utility
Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
28 Nov 23
Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein.
Zezhi Jesse Shao, Raizza Berania Florida, Ching-Yuan Li, Lee Alani Selvey
Filed: 12 Aug 21
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
26 Oct 23
Provided are methods of treatment of alopecia areata comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof.
Catherine M Crosby, Gurpreet Ahluwalia, Andrew Christopher Wesley Selfridge
Filed: 6 Jan 21
Utility
Substituted 3-phenoxyazetidin-1-yl-pyrazines
10 Oct 23
Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
Filed: 29 Mar 21
Utility
Cannabinoid receptor modulators
3 Oct 23
Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
Filed: 17 Sep 21
Utility
Methods of Treatment
21 Sep 23
Provided is a method of treatment of a 5-hydroxytryptamine (HT)2C receptor-associated disorder comprising: prescribing and/or administering to an individual in need thereof, (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Dolly PARASRAMPURIA, Chadwick J. OREVILLO, Philip PERERA
Filed: 9 Mar 23
Utility
Diaryl and Arylheteroaryl Urea Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful for the Prophylaxis and Treatment of Disorders Related Thereto
7 Sep 23
Bradley Teegarden, Honnappa Jayakumar, Hongmei Li, Sonja Strah-Pleynet, Peter I. Dosa
Filed: 13 Dec 22
Utility
Cannabinoid receptor modulators
5 Sep 23
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.
Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
Filed: 18 Sep 20
Utility
SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
17 Aug 23
Robert M. Jones, Daniel J. Buzard, Sangdon Han, Sun Hee Kim, Juerg Lehmann, Brett Ullman, Jeanne V. Moody, Xiuwen Zhu, Scott Stirn
Filed: 11 Aug 22
Utility
Compounds and Methods for Treatment of Primary Biliary Cholangitis
18 May 23
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC).
Cheryl Geraldine Lassen, Robert M. Jones, Que Liu, Ronald J. Christopher
Filed: 18 Nov 22
Utility
3-PHENOXYAZETIDIN-1-YL-HETEROARYL Pyrrolidine Derivatives and the Use Thereof As Medicament
27 Apr 23
Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
Filed: 9 Sep 22
Utility
Modulators of the Prostacyclin (PGI2) Receptor Useful for the Treatment of Disorders Related Thereto
20 Apr 23
Thuy-Anh TRAN, Weichao CHEN, Bryan A. KRAMER, Abu J.M. SADEQUE, Anna SHIFRINA, Young-Jun SHIN, Pureza VALLAR, Ning ZOU
Filed: 7 Jun 22
Utility
Compounds and Methods for Treatment of Inflammatory Bowel Disease with Extra-intestinal Manifestations
23 Mar 23
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(triflu-oromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of extra-intestinal manifestations (EIM) in an individual with inflammatory bowel disease (BBD) and for the treatment of pyoderma gangrenosum (PG).
Cheryl Geraldine Lassen
Filed: 18 Oct 22
Utility
5-HT2C receptor agonists and compositions and methods of use
21 Mar 23
The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor.
Graeme Semple, Albert S. Ren, Thomas O. Schrader, Michelle Kasem, Xiuwen Zhu
Filed: 19 Oct 20
Utility
5-HT2C Receptor Agonists and Compositions and Methods of Use
23 Feb 23
Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
Filed: 10 Jun 22
Utility
Compounds and Methods for Treatment of Visceral Pain
2 Feb 23
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof and their use in methods for the alleviation and/or treatment of visceral pain, for example abdominal pain; pelvic pain; male pelvic pain; pain from an internal organ; bladder pain; painful bladder syndrome; post-surgical abdominal pain (e.g., GI resection, hysterectomy, oophorectomy, C-section, and the like); or pain arising from or related to: pancreatitis (e.g., chronic pancreatitis), prostatitis (e.g., chronic prostatitis), inflammatory bowel disease (e.g., Crohn's disease), endometriosis, interstitial cystitis, prostatitis (e.g., chronic prostatitis), epididymitis (e.g., chronic epididymitis), or post-surgical abdominal lesions.
Cheryl Geraldine Lassen, Marcelo Fabian Piccirillo
Filed: 21 Jun 22
Utility
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
24 Jan 23
The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor and are therefore useful in the treatment of CB2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and Parkinson's disease.
Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter
Filed: 16 Mar 21